Fueling Digital Biology: Inside Isomorphic Labs’ $2B Raise

What does Isomorphic Labs do (problem and solution) ?

Let’s talk about building something that actually matters. The reality is, traditional drug discovery is a slow, painful grind. Researchers spend years manually studying the intricate proteins that make up disease-causing cells just to find a “binding pocket”. That is the specific entry point a drug needs to get into a cell to neutralize it. And even if your team manages to find it, you still have to figure out if your therapeutic compound will actually stick. Most iterations fail, draining years of time and capital.

Isomorphic Labs is tearing up that old playbook. Spun out of Alphabet’s Google DeepMind in 2021, the company is led by Demis Hassabis-who actually won half the 2024 Nobel Prize in chemistry for his work on AlphaFold 2. They are rebuilding the process from first principles. Their engine is called IsoDDE. It is fast. It is relentless. It is precise.

Built alongside AlphaFold 3-which itself jumped accuracy by more than 50% on certain tasks-IsoDDE automates the manual research workflows that normally bleed a startup’s runway dry. It requires a relatively limited amount of data about a protein to start hunting for those elusive binding pockets. When tested on the “Runs N’ Poses” benchmark, IsoDDE more than doubled AlphaFold 3’s score on the hardest tasks.

But it goes further. After identifying a target, it predicts the compound’s “binding affinity”-its actual ability to successfully attach to a protein. So, you aren’t just guessing anymore. You are computing with significantly higher accuracy than earlier methods.

Why this company raised $2Billion- main reasons?

Let’s be honest. Building category-defining technology burns capital. You need elite talent, massive compute power, and endless iterations. Isomorphic Labs recently secured a $600 million Series B at a $3.5 billion valuation. Now, reports indicate they are in talks to raise a massive new round worth over $2 billion. Thrive Capital is expected to lead this, with Alphabet continuing to chip in. Why such a staggering number? The reasons are intensely practical.

First, scaling an engine like IsoDDE to analyze small molecules and predict biological structures requires deep pockets. They reportedly plan to use this funding to enhance the engine itself. AI models devour compute and data, and processing that at scale is not cheap.

Second, it is about scaling operations and expanding their footprint. Isomorphic Labs already has headquarters in London and a second location in Switzerland. But building a global presence takes serious cash. They recently appointed Dr. Ben Wolf as Chief Medical Officer to establish a concrete US presence.

Here is the kicker: they aren’t just building software for other pharma companies to use. Transitioning an AI-designed molecule from a computer screen simulation into actual, physical clinical trials requires regulatory navigation, intense testing, and immense capital.

Vision and Future plans of the company.

What does the endgame look like here? Isomorphic Labs doesn’t just want to build a better software tool. Their mission is to redefine drug discovery using artificial intelligence and ultimately find cures for some of humanity’s most devastating diseases. And they are not doing it alone.

They kicked off 2024 by inking massive strategic collaborations with pharmaceutical giants Eli Lilly and Novartis. We are talking about multi-target research deals focused entirely on small molecule therapeutics. The Eli Lilly deal alone handed them $45 million upfront, with the potential for up to $1.7 billion in performance-based milestone payments, plus royalties. The Novartis collaboration brought another $37.5 million upfront, with up to $1.2 billion in potential milestones. These partnerships validate their technology and give them the shared expertise to push their proprietary platform to the absolute limit.

So, where are they heading next? The timeline is moving aggressively. They are transitioning from theory to practice. Reports indicate Isomorphic Labs is preparing to launch trials for its AI-designed drugs, eyeing its first actual drug trials in 2026. It is a huge bet. It’s lonely at the frontier. It’s hard. But if they pull this off, the timeline of how we cure diseases will never be the same.

Let’s be honest. You don’t raise $600 million-let alone negotiate a $2 billion mega-round without some serious heavy hitters on your cap table. The reality is, Isomorphic Labs is backed by the absolute elite of the venture and tech worlds.

First, you have Alphabet. They are the original backer, considering Isomorphic spun out of Google DeepMind, and they are continuing to pour in follow-on capital. And they didn’t stop there. Google Ventures, or GV, also jumped into the mix to participate in the funding. But who is leading the charge from the outside? Thrive Capital. They led the $600 million Series B and are reportedly the ones stepping up to lead the new $2 billion round. Here is the kicker: Thrive is the exact same heavyweight investor backing OpenAI. So, they clearly know what generational AI infrastructure looks like.

And to round out that tier-one syndicate, Andreessen Horowitz is also on the cap table. It is a short list. It is deeply connected. It is exactly the kind of financial firepower you need when your mission is to fundamentally rebuild how we cure diseases.

Sources used for the research

1. Alphabet’s Isomorphic Labs reportedly raising $2B+ for its medical research AI – SiliconANGLE
2. ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH LILLY
3. Isomorphic Labs – 2026 Company Profile, Team, Funding, Competitors & Financials – Tracxn
4. Isomorphic Labs Raises $600M in Series B – SalesTools AI